OncoMatch/Clinical Trials/NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms
Is NCT05544019 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SGR-1505 for mature b-cell neoplasm.
Treatment: SGR-1505 — The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner Health - MD Anderson Cancer Center · Gilbert, Arizona
- Christiana Care Hospital - Helen F Graham Cancer Center · Newark, Delaware
- Napa Research · Pompano Beach, Florida
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Regional Cancer Care Associates · Hackensack, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify